Novartis Flubs Primary Endpoint With Heart Drug Serelaxin
March 22, 2017 at 12:00 PM EDT
Novartis has reported that its 4-year study of the heart drug serelaxin has flubbed the primary endpoint, failing to significantly cut the rate of cardiovascular death or reduce worsening heart failure among patients with acute heart failure.